RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 901–999 of 999
Genetic Markers in Sporadic Tumors
Tamborini, E., Perrone, F., Frattini, M., Negri, T., Aiello, A., Gloghini, A., Carbone, A., Pilotti, S., & Pierotti, M. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_3 · Cited by 8
Huang, M., Liu, H., Yen, L.-C., Chang, J.-Y., Huang, J.-J., Wang, J., Hsiao, C.-P., & Lin, S. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-147 · Cited by 9
Molecular Biology of Colon Cancer
Grady, W. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-215-1_1 · Cited by 9
Amler, L. C., Goddard, A. D., & Hillan, K. J. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.048 · Cited by 8
Oncogenomics Methods and Resources
Furney, S. J., Gundem, G., & López-Bigas, N. (2012) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069229 · Cited by 10
“Initial large-scale sequencing efforts focused on signaling pathways previously known to be mutated in at least one gene (Davies et al. 2002; Rajagopalan et al. 2002).”
Wang, W., Wang, R., Han, X., Zhang, W., Zhu, L., & Gu, Y. (2024) · Medicine · doi:10.1097/md.0000000000037693 · Cited by 11
“…H’s and Blaker H’s studies all demonstrated that MSI-H CRCs have a significantly higher incidence of BRAF mutations and a lower incidence of KRAS mutations compared to MSS CRCs. [31,32] However, in our study, we did not observe any correlation between MSI status and BRAF V600E mutations.”
A Two-Hybrid Approach to Identify Inhibitors of the RAS–RAF Interaction
Khazak, V., Eyrisch, S., Kato, J., Tamanoi, F., & Golemis, E. A. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00010-5 · Cited by 7
Nemo-like kinase expression predicts poor survival in colorectal cancer
Chen, J., Han, Y., Zhao, X., Yang, M., LIU, B., Xi, X., XU, X., Liang, T.-J., & Xia, L. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2851 · Cited by 7
Buxhofer‐Ausch, V., Ausch, C., Zeillinger, R., Oberkanins, C., Dandachi, N., Reiner‐Concin, A., & Kriegshäuser, G. (2013) · Europe PMC (PubMed Central) · doi:10.3233/dma-120960 · Cited by 7
Liu, J., Wang, Y., Jiang, H., Yu, X., & Xu, N. (2019) · Medicine · doi:10.1097/md.0000000000014326 · Cited by 7
Effect of EI24 expression on the tumorigenesis of Apc colorectal cancer mouse model
Nam, T. W., Park, S. Y., Lee, J. H., Roh, J.-I., & Lee, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.186 · Cited by 7
Reynolds, I. S., O’Connell, E., Fichtner, M. W., Blümel, A. M., Mason, S., Kinross, J. K., McNamara, D. A., Kay, E. W., O’Connor, D. P., Das, S., et al. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001825 · Cited by 9
Araújo, R. L. C., da Fonseca, L. G., Silva, R. O., Linhares, M. M., & Usón, P. L. S. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-616 · Cited by 8
“On the other hand, CRC related to inherited Lynch syndrome can present only with KRAS , but eventually not BRAF mutations (11).”
Review: Medical treatment of advanced colorectal cancer in 2009
Grothey, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009343302 · Cited by 7
“It increasingly appears that patients with advanced CRC must have tumor with wildtype KRAS and wild-type BRAF in order for EGFR antibodies to be effective (Figure 1) [Amado et al. 2008; Artale et al. 2008; Bokemeyer et al. 2008; Di Nicolantonio et al. 2008; Karapetis et al. 2008; Van Cutsem et al. 2008; Di Fiore et al…”
BackgroundMethodImpact of cetuximab in current treatment of metastatic colorectal cancer
Sotelo, M. J., Valera, J. S., & Díaz‐Rubio, E. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.883376 · Cited by 8
“Mutations of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) are present in 4 -- 15% of colorectal cancers [41-43], and appear to be mutually exclusive with KRAS mutations [36,42,44,45].”
BackgroundCheung, D. Y., & Kim, J. K. (2013) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2013.61.3.117 · Cited by 7
Monochromatic x-ray sampling streak imager for fast-ignitor plasma observation
Tanabe, M., Fujiwara, T., Fujioka, S., Nishimura, H., Shiraga, H., Azechi, H., & Mima, K. (2008) · Review of Scientific Instruments · doi:10.1063/1.2965145 · Cited by 7
B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in Xenopus egg extracts
Yue, J., Xiong, W., & Ferrell, J. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209354 · Cited by 7
“…be mutated in more than 60% of melanomas and a substantial percentage of many other human cancers (Davies et al., 2002; Pollock and Meltzer, 2002; Rajagopalan et al., 2002; Chong et al., 2003; Pollock et al., 2003; Wan et al., 2004), suggesting that this Raf family member is of particular…”
BackgroundCliques and Schisms of Cancer Genes
Campbell, P. J. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.009 · Cited by 7
“Several well-documented examples of such associations have emerged, including mutual exclusivity of RAS-pathway mutations in colorectal cancers (Rajagopalan et al., 2002) and co-occurrence of KRAS, CDKN2A, and TP53 mutations in pancreatic cancer (Bardeesy and DePinho, 2002).”
BackgroundChen, H., Wang, A., Wang, J., Ze-ming, H., Mao, Y., & Liu, L. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03192-z · Cited by 8
Epithelial Cell Signalling in Colorectal Cancer Metastasis
Saucier, C., & Rivard, N. (2010) · Cancer metastasis · doi:10.1007/978-90-481-8833-8_8 · Cited by 11
“B-RAF, a member of the Raf family, are associated with increased kinase activity and have been found in 10–15% of CRCs; many of those with such mutations are at early Dukes’ stage (A and B) (Davies et al., 2002; Rajagopalan et al., 2002).”
BackgroundThe DNA mismatch repair pathway
Martin, S. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00006-1 · Cited by 10
Morrison, D. K. (2004) · Nature · doi:10.1038/428813a · Cited by 7
Consensus molecular subtype transition during progression of colorectal cancer
van de Weerd, S., Torang, A., Zwager, L. W., Koelink, P. J., Koster, J., Bastiaansen, B. A., Lammers, V., Longobardi, C., Roodhart, J. M., van Krieken, J. H., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6176 · Cited by 6
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
Sommer, A. K., Paske, I. T., Jansen, E. A. M., Gschwind, A., Demidov, G., Steinke‐Lange, V., Spier, I., Steyaert, W., Yaldiz, B., Steehouwer, M., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2025.10.011 · Cited by 12
Uchida, S., Kojima, T., & Sugino, T. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610206 · Cited by 7
Rasool, M., Carracedo, Á., Sibiany, A., Al-Sayes, F., Karim, S., Haque, A., Pushparaj, P. N., Asif, M., & Achakzai, N. M. (2021) · Bioengineered · doi:10.1080/21655979.2021.1960715 · Cited by 7
“Furthermore, the majority of KRAS mutations have been reported in exon-2 of the KRAS gene, whereas only 1% in exon-3 and 4% in exon-4 mutations are found in CRCs [28].”
BackgroundInfluentialBusby, K., & Morris, A. G. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.018655 · Cited by 6
“Colorectal cancers with BRAF mutations do not have K-ras mutations.”
BackgroundZecchin, D., Arena, S., Martini, M., Sassi, F. P., Pisacane, A. M., Nicolantonio, F. D., & Bardelli, A. (2013) · Human Mutation · doi:10.1002/humu.22234 · Cited by 6
“…exclusivity pattern of mutations often involves genes acting in common signaling pathways, for example BRAF V600E mutations typically occur in a mutually exclusive relationship with RAS alterations in colorectal cancer, ovarian cancer and melanomas [Davies et al., 2002; Rajagopalan et al., 2002].”
BackgroundSelf-citationEssential genes in thyroid cancers: focus on fascin
Samimi, H., Zaki‐Dizaji, M., Ghadami, M., Fazeli, S. A. S., Khashayar, P., Soleimani, M., Larijani, B. A., & Haghpanah, V. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-32 · Cited by 6
BRAF Mutations and their Implications in Molecular Targeting Therapies for Gastrointestinal Cancers
Shimoyama, S. (2011) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000e102 · Cited by 6
“In this regard, mutation analyses for RAF proteins, downstream proteins to KRAS in the MEK/ERK pathway, have been attractive targets for patient selection before considering anti-EGFR therapies because KRAS and BRAF mutation is usually mutually exclusive [17-19] - although double mutation of KRAS and BRAF does occur i…”
Lack of BRAFV600E mutation in stage I and II of colorectal cancer.
Molaei, M., Farahani, R. K., Maftouh, M., Taleghani, M. Y., Vahdatinia, M., Khatami, F., Mojarad, E. N., Aghdae, H. A., Aboutorabi, A., & Zali, M. R. (2016) · Gastroenterology and hepatology from bed to bench. · Cited by 7
Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer
Grellety, T., Gros, A., Pédeutour, F., Merlio, J., Duranton‐Tanneur, V., Italiano, A., & Soubeyran, I. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1991-0 · Cited by 6
“Our data indicate that the dogma that of the genes in the MAPK pathway only a single one is ever mutated in CRC is not valid in a small proportion of cases.”
BackgroundInfluentialA study of BRAF mutation in colorectal carcinoma in Indian population
Saxena, S., Srinivas, V., Deb, P., Raman, D. K., & Jagani, R. (2017) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_26_17 · Cited by 7
Implications of the HDAC6-ERK1 feed forward loop in immunotherapy
Zhang, X. M. (2018) · Journal of Immunological Sciences · doi:10.29245/2578-3009/2018/3.1143 · Cited by 5
Mousavi, N., Truelsen, S. L. B., Hagel, G., Jørgensen, L. N., Harling, H., Wielenga, V. T., Melchior, L. C., Thysen, A. H., Heegaard, S., & Thastrup, J. (2019) · International Journal of Experimental Pathology · doi:10.1111/iep.12308 · Cited by 6
Wu, D., Chen, D., Shi, W., Liu, W., Zhou, W., & Qian, J. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/9936932 · Cited by 6
“Rajagopalan et al. [16] used the HumanMethylation 450 array to identify methylated genes in SSA compared with normal mucosa, followed by RNA sequencing.”
Haefliger, S., Marston, K., Alborelli, I., Stauffer, E.-J., Gugger, M., Jermann, P. M., Hoeller, S., Tornillo, L., Terracciano, L., Bihl, M., et al. (2022) · Pathobiology · doi:10.1159/000526117 · Cited by 6
p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors
Maietta, I., Peschio, F. D., Buonocore, P., Viscusi, E., Laudati, S., Iannaci, G., Minopoli, M., Motti, M. L., & Falco, V. D. (2022) · Cancers · doi:10.3390/cancers15010121 · Cited by 7
Klingbiel, D., & Tejpar, S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5226 · Cited by 8
Wen, Y., Zhang, S., Yang, J., & Guo, D. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109546 · Cited by 6
Molecular Causes of the Cardio-Facio-Cutaneous Syndrome
Tidyman, W. E., & Rauen, K. A. (2008) · Monographs in human genetics · doi:10.1159/000164843 · Cited by 7
Monstein, H., Fransén, K., Dimberg, J., & Söderkvist, P. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01296.x · Cited by 6
Pattalachinti, V. K., Haque, E., Yousef, M., Yousef, A. M. G., Chowdhury, S., Overman, M. J., Parseghian, C. M., Morris, V. K., Kee, B. K., Huey, R. W., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00821-z · Cited by 5
Olyaei, A., Shalbafan, M., & Sadeghpour, M. (2024) · New Journal of Chemistry · doi:10.1039/d4nj00983e · Cited by 5
Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review
Gao, Y., & Zheng, H. S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104484 · Cited by 8
Hyperplastic Polyposis Syndrome Identifi ed with a BRAF Mutation
Ahn, H. S., Hong, S. J., Kim, H. K., Yoo, H. Y., Kim, H. J., Ko, B. M., & Lee, M. S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.280 · Cited by 5
“BRAF mutations have recently been found in 5% to 15% of CRCs.(7-9) We present a case of a 34-yearold young woman with HPS who had a BRAF mutation.”
BackgroundInfluentialMorikawa, T., Inada, R., Nagasaka, T., Mori, Y., Kishimoto, H., Kawai, T., Umeda, Y., Mishima, H., Goel, A., & Fujiwara, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.7553 · Cited by 5
Morris, V. K. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00429-z · Cited by 8
New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients
Ruffinelli, J. C., Vivas, C. S., Pamplona, R. S., & Moreno, V. R. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1826305 · Cited by 4
Genetic and epigenetic characteristics of patients with colorectal cancer from Uruguay
Vital, M., Carusso, F., Vergara, C., Neffa, F., Valle, A. D., & Esperón, P. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154264 · Cited by 5
Magnusson, M. I., Agnarsson, B. A., Jonasson, J. G., Tryggvason, T., Aeffner, F., le Roux, L., Magnúsdóttir, D. N., Gunnarsdottir, H. S., Alexiusdottir, K. K., Gunnarsdóttir, K., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02374-z · Cited by 7
“BRAF and KRAS mutations in cancers have been shown be mutually exclusive [35], and therefore, assessment of both with respect to survival is in order.”
BackgroundBRAF Non-V600 Mutations in Metastatic Colorectal Cancer
Liu, J., & Xie, H. (2023) · Cancers · doi:10.3390/cancers15184604 · Cited by 5
“BRAF-mutant CRC, especially those with non-V600 mutations, can also have mutations in other BRAF-interacting proteins due to the complex nature of the MAPK pathway [18–23].”
Sekal, M., Ameurtesse, H., Chbani, L., Ouldim, K., Bennis, S., Abkari, M. E., Boulouz, A., Benajah, D., Benjelloun, B., Ousadden, A., et al. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0326-9 · Cited by 7
“Approximately 20 % of CRCs are CIMP-high tumors and are thought to arise from serrated polyps [13].”
BackgroundInfluentialArentz, G., Chataway, T., Condina, M. R., Price, T. J., Hoffmann, P., & Hardingham, J. E. (2012) · ISRN Molecular Biology · doi:10.5402/2012/706545 · Cited by 6
Molecular Taxonomy and Tumourigenesis of Colorectal Cancer
Biswas, S., Holyoake, D., & Maughan, T. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.11.001 · Cited by 7
Huang, C., Huang, S., Chien, C., Lee, H. H., Yang, S.-H., Chang, C., & Lee, C. (2016) · Oncology Letters · doi:10.3892/ol.2016.5275 · Cited by 5
“CRC patients with MSS have aberrant activation of the MAPK pathway (12,13,17).”
InfluentialHayes, T. K., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_6 · Cited by 9
Genetic heterogenety of tumour-like lesions of bones in maxillofacial area
Свиридов, Е. Г., Kadykova, A. I., Redko, N., Drobyshev, A. Y., & Deev, R. V. (2019) · Genes and Cells · doi:10.23868/201903006 · Cited by 5
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 6
Xue, X., Li, X., Pan, Z., Zhao, L., & Ding, Y.-Q. (2017) · PubMed · Cited by 5
Statuts MMR et BRAF dans les cancers colorectaux : intérêts pour la prise en charge thérapeutique ?
Cohen, R., Cervera, P., Svrcek, M., Dumont, C., Garcia‐Larnicol, M., Chibaudel, B., de Gramont, A., Pocard, M. D., Duval, A., Fléjou, J., et al. (2015) · Bulletin du Cancer · doi:10.1016/s0007-4551(15)31220-0 · Cited by 5
Marsit, C. J., Houseman, E. A., Nelson, H. H., & Kelsey, K. T. (2008) · Journal of Cancer Epidemiology · doi:10.1155/2008/215809 · Cited by 5
“The mechanism that underlies the connection between KRAS mutation and increased methylation propensity remains unclear; indeed, the same can be said for the established connection between BRAF mutation and CIMP, although it is known that these two oncogenes operate in the same cell signaling pathway [48, 53].”
BackgroundAssociation of Thyroid Lymphoma and Tall Cell Thyroid Papillary Carcinoma
zquez, P. L.-V., Mosteiro, M. N., P�ramo, C., lez-Carrer, J. N. G., & García-Mayor, R. V. (2007) · The Endocrinologist · doi:10.1097/01.ten.0000257448.25668.b9 · Cited by 5
Ando, Y., Sakurai, T., Ozaki, K., Matsui, S., Mukai, T., Yamaguchi, T., Akiyoshi, T., Nakayama, I., Shigematsu, Y., Oba, A., et al. (2024) · Surgical Case Reports · doi:10.1186/s40792-024-01994-8 · Cited by 4
Precision Oncology Framework Using Circulating Tumor Cells
Kakizaki, F., Oshiro, K., Enoki, Y., Kawanishi, K., Masuda, N., Maekawa, H., Matsubayashi, J., Kawashima, M., Miyoshi, H., Takemura, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125539 · Cited by 6
Gerger, A., Eisterer, W., Fuxius, S., Bastian, S., Koeberle, D., Welslau, M., Akhoundova, D., MAAS, C., Uhlig, J., Fenchel, K., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.15982 · Cited by 4
Targeted Therapies in Melanoma: Successes and Pitfalls
Palmieri, G., Colombino, M., Cristina, M., Ascierto, P. A., Lissia, A., & Cossu, A. (2013) · InTech eBooks · doi:10.5772/53624 · Cited by 9
“On this regard, KRAS altera‐ tions mostly occur in gastrointestinal cancer [17-18], HRAS alterations are frequently ob‐ served in bladder cancer, and NRAS is mutated in 15-25% of melanomas [17-18].”
BackgroundColorectal Cancers with the Uncommon Findings of KRAS Mutation and Microsatellite Instability
Zauber, P., Marotta, S. P., & Sabbath‐Solitare, M. (2015) · Cytogenetic and Genome Research · doi:10.1159/000441086 · Cited by 4
“BRAF and KRAS are members of the same signaling pathway, and it has been shown that BRAF mutations in colorectal cancers are mutually exclusive of KRAS mutations [Rajagopalan et al., 2002; Deng et al., 2004].”
BackgroundThe Genetics of Colorectal Cancer
Kaz, A. M., & Grady, W. M. (2010) · Cancer metastasis · doi:10.1007/978-90-481-8833-8_3 · Cited by 4
Tornillo, L., Lehmann, F. S., Garofoli, A., Paradiso, V., Ng, C. K. Y., & Piscuoglio, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668466 · Cited by 5
Paolucci, I., Lin, Y., Kawaguchi, Y., Maki, H., Jones, A. K., Calandri, M., Kopetz, S., Newhook, T. E., Brock, K. K., Vauthey, J., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02030-y · Cited by 4
“This is supported by the fact that these mutations are mostly mutually exclusive and overlap functionally [13, 14].”
BackgroundCetuximab Therapy and RAS and BRAF Genotype
Dean, L., & Kane, M. S. (2020) · Europe PMC (PubMed Central) · Cited by 9
Molecular biology of colorectal cancer in clinical practice
Kit, O. I., & Vodolazhsky, D. I. (2015) · Molecular Biology · doi:10.1134/s0026893315040081 · Cited by 4
Rihawi, K., Giampieri, R., Scartozzi, M., Pusceddu, V., Bonotto, M., Fasola, G., Cascinu, S., & Aprile, G. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1054479 · Cited by 4
“The most frequently reported BRAF mutation (> 95%) is the V600E mutation within the kinase activation domain of the BRAF protein, which results in the substitution of valine with glutamate at codon 600 [39-41].”
BackgroundL'instabilité des microsatellites dans les cancers du côlon
Lamoril, J., Deybach, J., & Bouizegarène, P. (2006) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2006.04.006 · Cited by 4
Urso, E. D. L., Agostini, M., Pucciarelli, S., Rugge, M., Bertorelle, R., Maretto, I., Bedin, C., D’Angelo, E., Mescoli, C., Zorzi, M., et al. (2012) · Tumor Biology · doi:10.1007/s13277-011-0312-0 · Cited by 4
“The V600E hot spot mutation on BRAF, a gene involved in the RAS/RAF protein kinase pathway [16], is more frequently detected in MSI-H than in stable tumours and is mutually exclusive with germline MMR deficiency [17, 18].”
BackgroundPathology and Molecular Pathology of Colorectal Cancer
Poulin, E. J., Shen, J., Gierut, J. J., & Haigis, K. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-35153-7_22 · Cited by 5
Degeling, K., Wong, H., Koffijberg, H., Jalali, A., Shapiro, J., Kosmider, S., Wong, R., Lee, B., Burge, M., Tie, J., et al. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00951-1 · Cited by 5
Insights into familial colon cancer: The plot thickens
Sinicrope, F. A. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00719-0 · Cited by 4
Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials
Bhatia, S., Emdad, L., Das, S. K., Hamed, H. A., Dent, P., Sarkar, D., & Fisher, P. B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.884558 · Cited by 4
“Activating mutations of RAS have been detected in 15 -- 20% of melanomas, and almost exclusively involve the NRAS isoform [10-12].”
Alejandre, C., Calle-Espinosa, J., & Iranzo, J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012081 · Cited by 5
“Two classical examples are the synergistic interaction between activating mutations in MYC and amplification of RAS [29] and the mutually exclusive relationship between alterations in KRAS and BRAF across many cancer types [30].”
Desouza, A. L., Nadkarni, S., Roy, S., Kataria, P., Ramaswamy, A., & Ostwal, V. S. (2024) · Springer eBooks · doi:10.1007/978-981-99-3378-5_40 · Cited by 5
Facteurs pronostiques des cancers colorectaux localisés
Bibeau, F., Hazebroucq, J., Pierson, R., & Khellaf, L. (2013) · Côlon & Rectum · doi:10.1007/s11725-013-0469-3 · Cited by 3
Simultaneous Detection of Colorectal Cancer Mutations in Stool Samples with Biochip Arrays
Murray, H. A., Latten, M. J., Cartwright, A., McAleer, D., & Fitzgerald, S. P. (2009) · Journal of Medical Biochemistry · doi:10.2478/v10011-009-0028-5 · Cited by 3
“Mutations tend to occur in a mutually exclusive relationship with K-ras mutations (7, 9, 11).”
BackgroundEGFR and FGFR in Growth and Metastasis of Colorectal Cancer
Dariya, B., Merchant, N., Aliya, S., Alam, A., & Nagaraju, G. P. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_11 · Cited by 3
BRAF mutations as a therapeutic target in metastatic colorectal cancer patients: a long due success
Şahin, İ. H., & Klostergaard, J. (2019) · Colorectal Cancer · doi:10.2217/crc-2019-0012 · Cited by 3
Lan, Y., Liu, W., Zhang, W., Hu, J. R., Zhu, X., Wan, L., Suru, A., Ping, Y., & Xiao, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.4039 · Cited by 3
Chakraborty, B., Agarwal, S., Kori, S. K., Das, R., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230505165031 · Cited by 3
Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma
Kozyra, P., & Pitucha, M. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673258495231011065225 · Cited by 4
Immune Checkpoint Inhibitors in BRAF -Mutated Advanced Colorectal Cancer
Kassab, R., Khalil, M. A., Kassab, J. T., & Kourié, H. R. (2023) · Future Oncology · doi:10.2217/fon-2022-0978 · Cited by 3
Wnt/β-Catenin Signaling and Oral Cancer Metastasis
Zhou, G. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0775-2_11 · Cited by 6
“Similarly, mutations in the other genes the RAS pathway, such as BRAF (Rajagopalan et al. 2002), or in members of tyrosine kinome and phosphatome (Bardelli et al.”
BackgroundMcCubrey, J. A., Franklin, R. A., Bertrand, F. E., Taylor, J. R., Chappell, W. H., Midgett, M. L., Wong, E. W. T., Abrams, S. L., Stadelman, K. M., Misaghian, N., et al. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-474-2_7 · Cited by 3
Lièvre, A., & Laurent‐Puig, P. (2009) · Personalized Medicine · doi:10.2217/17410541.6.2.145 · Cited by 3
Zhang, Y., Xu, L., Qiu, J., Li, Z., Li, L., Ren, G., Dong, A., Li, B., Ge, M., Meng, S., et al. (2010) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-010-0444-2 · Cited by 3
BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias
Velangi, M., Matheson, E. C., Taylor, P., Jackson, G. H., Hall, A. G., & Irving, J. A. E. (2004) · Leukemia · doi:10.1038/sj.leu.2403286 · Cited by 3
“1 In colorectal tumours, BRAF mutations were found in 32 of 330 samples, and there was a highly significant incidence in tumours shown to be mismatch repair (MMR) deficient”
BackgroundMutación del gen BRAF en pacientes con cánceres de colon y recto con KRAS no mutado
Roa, I. S., Game, A., Bizama, C., & Schalper, K. A. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000100009 · Cited by 8
Bidzhekov, K., Hautmann, M. B., Semisch, M., Weber, C., Engelmann, B., & Hatzopoulos, A. K. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00123.x · Cited by 3
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.